News
BNTC
4.800
+0.42%
0.020
Weekly Report: what happened at BNTC last week (0408-0412)?
Weekly Report · 2d ago
Wall Street Breakfast: The Week Ahead
Geopolitical tensions in the Middle East will hold the focus of markets to start the week after Iran's attack on Israel. The economic calendar will continue to garner attention with retail sales and industrial production on the docket. The first quarter earnings season will pick up pace next week.
Seeking Alpha · 3d ago
Netflix, Johnson & Johnson, Procter & Gamble And Baidu On Watch
Netflix, Johnson & Johnson, Procter & Gamble And Baidu On Watch. The earnings calendar ramps up in the week ahead with Goldman Sachs, Netflix, and Proctor & Gamble set to report. The Federal Reserve will release the latest Beige Book report. In the tech sector, baidu will host its annual flagship AI developer conference.
Seeking Alpha · 4d ago
Catalyst Watch: Boeing hearing, Bitcoin halving event and new eyes on Reddit
Seeking Alpha's Catalyst Watch looks at events that may impact stock prices next week. The Bitcoin halving event will be a major focus in the cryptocurrency world. Options trading volume is elevated on electric vehicle stocks Nikola and Rivian. The four-day NAB Show in Las Vegas will focus on cybersecurity and the role of AI in media.
Seeking Alpha · 5d ago
Weekly Report: what happened at BNTC last week (0401-0405)?
Weekly Report · 04/08 12:04
Weekly Report: what happened at BNTC last week (0325-0329)?
Weekly Report · 04/01 12:01
Weekly Report: what happened at BNTC last week (0318-0322)?
Weekly Report · 03/25 12:04
Weekly Report: what happened at BNTC last week (0311-0315)?
Weekly Report · 03/18 12:02
Weekly Report: what happened at BNTC last week (0304-0308)?
Weekly Report · 03/11 11:58
Benitec Biopharma Awards Stock Options to Top Executives
TipRanks · 03/08 21:33
JAGX, BBAI and BNTC among mid-day movers
On the Move JAGX, BBAI and BNTC among mid-day movers. Phunware and Ocean Biomedical are among the biggest gainers in the biotechnology sector. In the tech sector, a number of companies are reporting positive quarterly results.
Seeking Alpha · 03/04 17:35
12 Health Care Stocks Moving In Monday's Intraday Session
Ocean Biomedical (NASDAQ:OCEA) shares rose 55.0% to $3.1 during Monday's regular session. The company's market cap stands at $105.6 million. Jaguar Health (Jaguar Health) stock moved upwards by 54.8% during the session. Jin Medical International (Jin Medical International) and Ainos (AIMD) were also in the spotlight.
Benzinga · 03/04 17:34
Weekly Report: what happened at BNTC last week (0226-0301)?
Weekly Report · 03/04 12:01
Weekly Report: what happened at BNTC last week (0219-0223)?
Weekly Report · 02/26 12:19
Benitec Biopharma (BNTC) Price Target Increased by 66.67% to 10.20
NASDAQ · 02/24 22:56
Benitec Biopharma files for $125M mixed securities shelf
Seeking Alpha · 02/23 21:18
Benitec Biopharma Files For Mixed Shelf Of Up To $125M
Benzinga · 02/23 21:14
Weekly Report: what happened at BNTC last week (0212-0216)?
Weekly Report · 02/19 12:22
Benitec Biopharma Price Target Raised to $10.00/Share From $8.00 by JMP Securities
Dow Jones · 02/15 19:07
Benitec Biopharma Is Maintained at Market Outperform by JMP Securities
Dow Jones · 02/15 19:07
More
Webull provides a variety of real-time BNTC stock news. You can receive the latest news about Benitec Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About BNTC
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).